Bain Capital Life Sciences
SlowingFiled to raiseBoston, MABiotechnology, Healthcare, PharmaceuticalsLast fund filed 2024
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Bain Capital Life Sciences Fund IVFiled to raise in 2024, with no closing reported yet. | 2024 | Indefinite | $0 | 0 |
| Bain Capital Life Sciences Fund IIIFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
| Bain Capital Life Sciences Fund IIFiled to raise in 2019, with no closing reported yet. | 2019 | Indefinite | $0 | 0 |
| Bain Capital Life Sciences FundFiled to raise in 2016, with no closing reported yet. | 2016 | Indefinite |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Jeffrey Schwartz | Slowing | Biotech & pharma, Enterprise software, Climate & energy | 11 |
Classified sectors of Bain Capital Life Sciences’s own portfolio companies, based on 26 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Caduceus Capital | 4 | ADARx Pharmaceuticals, Arcutis Biotherapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics |
| Orbimed Asia Partners | 4 | ADARx Pharmaceuticals, Arcutis Biotherapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics |
| Orbimed Genesis | 4 | ADARx Pharmaceuticals, Arcutis Biotherapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics |
| $0 |
| 0 |
| 1 |
| Adam Koppel | Quiet | Biotech & pharma | 5 | 0 |
| Andrew Hack | Quiet | Biotech & pharma, Medical devices | 6 | 0 |
| Ricky Sun | Quiet | Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Bain Capital Life Sciences’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 270 Healthcare Growth |
| 2 |
| SpringWorks Therapeutics, SpringWorks Therapeutics |
| Atlas Venture | 2 | Editas Medicine, Xilio Therapeutics |
| Lightstone Singapore | 2 | GYNESONICS, Imperative Care |
| Lightstone Ventures | 2 | GYNESONICS, Imperative Care |
| Abingworth Bioventures | 1 | GYNESONICS |
| ARCH Venture Partners | 1 | Areteia Therapeutics |
| Bain Capital Ventures | 1 | LogicSource |
| BCV | 1 | LogicSource |
| Clarus | 1 | Annexon |
| Longitude 103.8 East | 1 | Aptinyx |
| Longitude Capital | 1 | Aptinyx |
| Longitude Prime | 1 | Aptinyx |
A shared board seat: a company where filings name a Bain Capital Life Sciences partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.